Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. Misses on Revenue, Stock Down 2.99%

Aurinia Pharmaceuticals reported a loss per share that exceeded expectations, which may indicate better cost management. However, the lack of revenue figures and guidance led to a negative stock reaction, with shares dropping nearly 3%. Investors may be cautious given the absence of detailed commentary from management.